Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2007

View Archived Issues

Medarex announces 2007 second quarter results

Subjective effects of memantine in smokers

Talnetant potentiates monoaminergic neurotransmission induced by atypical antipsychotics

Recent patent claims novel short peptides for the treatment of endometriosis

Seikagaku claims new drugs for osteoporosis

Novel oncolytic compounds reported in recent patents

Bayer and Nektar launch agreement on novel therapy for Gram-negative pneumonias

GammaCan obtains FDA orphan drug designation for VitiGam in melanoma

The Medicines Company files sNDA to expand Angiomax label

Welichem Biotech's antipsoriatic drug candidate enters phase I clinical trial

FDA issues not approvable letter for GSK's Advair 500/50

Neuromed and Merck & Co. discontinue development of NMED-160

Biomira and Merck amend Stimuvax collaboration

Positive interim results for Genaera's phase I study of trodusquemine for obesity

Abraxis and Biocon sign licensing agreement for commercialization of Abraxane

Epix cites results from phase IIa trial of 5-HT2B antagonist in COPD-associated PH

Phosphagenics cites positive phase Ib transdermal insulin clinical trial results

Particle-mediated delivery of H5N1 vaccine holds promise for the prophylaxis of influenza

Targeting amyloid-beta, a novel approach in glaucoma therapy

FDA approves Spectrum's SPI-1620 IND

FDA accepts Regeneron's BLA for IL-1 Trap rilonacept

Patient enrollment begins for ImClone's phase II study of IMC-11F8

IND for Active Biotech's phase II study of TASQ approved by FDA

Alnylam reports closing of Roche alliance

Sirtris begins phase Ib trial of SRT-501 for MELAS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...